oncolytic virotherapies

News

At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, now named Tudriqev and its first product.

Events

Partner Content

Join the 4th Oncolytic Virotherapy Summit in Boston

News

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.